FDA Accepts Bayer's Application for KERENDIA® to Treat Chronic Kidney Disease Without Diabetes

The U.S. Food and Drug Administration (FDA) has accepted Bayer's supplemental New Drug Application (sNDA) for KERENDIA® (finerenone). The application seeks to expand the treatment's indication to include adults with chronic kidney disease (CKD) who do not have diabetes and are receiving standard care. KERENDIA met its primary endpoint in a study, demonstrating a significant reduction in the rate of kidney function decline.